Companies › Chengdu New Radiomedicine Technology
4 active drug programs in 4 registered trials: 3 Phase 1, 1 Phase 3; Oncology; next expected readout Oct 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| NRT6003 Injection Yttrium-90 radioembolization using carbon microspheres | – | Phase 3 | Unresectable Hepatocellular Carcinoma | Oct 2027 |
| 177Lu-NRT6020 Injection FAP-targeting radiopharmaceutical for radionuclide therapy | FAP | Phase 1 | Solid Tumor Malignancy | Oct 2027 |
| 68Ga-NRT6020 Injection FAP-targeting radiopharmaceutical for PET imaging | FAP | Phase 1 | Solid Tumor Malignancy | Oct 2027 |
| NRT6008 | – | Phase 1 | Unresectable Pancreatic Cancer | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06911489 | 68Ga-NRT6020 Injection | Phase 1 | Solid Tumor Malignancy | Oncology | Oct 2027 |
| NCT06911489 | 177Lu-NRT6020 Injection | Phase 1 | Solid Tumor Malignancy | Oncology | Oct 2027 |
| NCT06900543 | NRT6003 Injection | Phase 3 | Unresectable Hepatocellular Carcinoma | Oncology | Oct 2027 |
| NCT06278454 | NRT6008 | Phase 1 | Unresectable Pancreatic Cancer | Oncology | Dec 2027 |
Blue Earth Diagnostics SOFIE Lantheus Medical Imaging Immunome Nanjing Sanhome Pharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.